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Purpose: To determine the intravitreal levels of vascular endothelial growth factor (VEGF) 
in eyes with anterior hyaloidal fibrovascular proliferation (AHFVP).
Methods: Three eyes of three patients who underwent vitrectomy for proliferative diabetic 
retinopathy (PDR) and subsequently developed an AHFVP (AHFVP group) were studied. We 
measured the level of VEGF in vitreous samples collected at the primary and following opera-
tions by enzyme-linked immunosorbent assay. The vitreous levels of VEGF in 25 eyes of 22 
patients with PDR were also studied as controls (PDR group).
Results: The averaged VEGF level in the samples collected at the primary surgery was 
1.98 ± 2.23 ng/mL in the PDR group, and it was 9.07, 1.94, and 8.07 ng/mL in the AHFVP 
cases. After the primary surgery, the VEGF level rose up to 49.50, 15.60, and 50.60 ng/mL at 
the subsequent surgeries for respective cases of the AHFVP group. These levels of VEGF were 
more than five times higher than the baseline at the primary surgery.
Conclusion: The subsequent increase of the VEGF level after the primary surgery in eyes with 
an AHFVP suggests that the vitreous levels of VEGF are associated with the development of 
the AHFVP although only three eyes were studied.
Keywords: VEGF, AHFVP, diabetic retinopathy
Introduction
An anterior hyaloidal fibrovascular proliferation (AHFVP) is a fibrous vascular prolif-
eration in the peripheral retina that can cause vitreous hemorrhage, retinal detachment, 
and ocular hypotension. These changes can then result in poor vision.1 An AHFVP 
develops postoperatively mainly in young patients with severe proliferative diabetic 
retinopathy (PDR) despite a complete removal of the vitreous and extensive retinal 
photocoagulation of the peripheral retina.
We questioned whether vascular endothelial growth factor (VEGF) plays a role 
in the development of AHFVPs because earlier studies found that the progression of 
diabetic retinopathy was associated with the vitreal levels of VEGF.2 Thus, the VEGF 
level in the vitreous is higher in eyes with more severe diabetic retinopathy, and the 
level affects the visual outcome negatively after vitrectomy.3 However, it has not been 
determined whether VEGF contributes to the development of AHFVPs.
The purpose of this study was to determine the level of VEGF in the vitreous of 
eyes with PDR at the primary surgery and also in eyes that developed an AHFVP 
after the surgery. We compared the VEGF level in vitreous samples collected at the 
time of the primary vitrectomy from patients who developed an AHFVP with that in 
patients with PDR who did not develop AHFVP.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Materials and methods
Patients
Three eyes of three patients (two men and one woman) 
who developed an AHFVP after vitrectomy for PDR were 
studied and placed in the AHFVP group. They were treated 
at the Vitreoretinal Disease Unit of the Iwate Medical 
University Hospital from July 2003 through June 2006. 
The three patients with an AHFVP had insulin-dependent 
diabetes. AHFVP was diagnosed in the eyes that had annular 
fibrovascular tissue at the vitreous base during the vitreous 
surgery (Figure 1). The ages of the patients were 24, 32, and 
49 years. Twenty-five eyes of 22 patients (18 men and four 
women) who underwent   vitrectomy for PDR from February 
2005 to March 2007 were studied as controls and placed in 
the PDR group. Their mean age was 43.2 ± 12.9 years with 
a range of 22–67 years. The   difference in the ages between 
the PDR and AHFVP groups was not significant.
This research was conducted in accordance with the 
Institutional Guidelines of Iwate Medical University, and 
the procedures conformed to the tenets of the Declaration 
of Helsinki. An informed consent was obtained for the 
  vitrectomy from all subjects after a full explanation of the 
nature of the experiment.
sample collection and measurement  
of VegF levels
Vitreous samples were collected at the beginning of the vitre-
ous surgery. In cases that developed AHFVP, samples were 
also collected at each vitrectomy to treat the AHFVP. The 
intravitreal VEGF levels were measured by   enzyme-linked 
immunosorbent assay (ELISA) using a kit for human VEGF 
(Quantikine; R&D Systems, Minneapolis, Minnesota, US). 
We incubated 200 µL of each sample in 96-well plates 
coated with human immunoglobulin G (IgG)-specific goat 
IgG for 2 hours at room temperature. After the incubation, 
the plate was washed, and a peroxidase-conjugated antibody 
was added and incubated for 2 hours at room temperature. 
The plate was washed again, and the substrate was added, 
and the optical density was measured at 450 and 620 nm 
using an absorption spectrophotometer. A standard curve 
was plotted from measurements made with the standard 
solutions and used to determine the concentration of VEGF 
in the sample.
Results
VegF levels in control eyes with 
proliferative diabetic retinopathy
The averaged level of VEGF in the PDR group that did not 
develop AHFVP was 1.98 ± 2.23 ng/mL (mean ± standard 
deviation) (Figure 2).
Clinical features of AhFVP cases
The VEGF levels in the vitreous humor are plotted for the 
three patients who developed an AHFVP after the primary 
  vitrectomy (Figure 2).
In Case 1 (black squares), the VEGF level was 9.07 ng/mL 
at the primary vitrectomy, which also included cataract sur-
gery. The VEGF level was markedly increased to 49.50 ng/mL 
in a vitreous sample collected during trabeculectomy for neo-
vascular glaucoma 7 weeks postoperatively even though the 
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Figure 2 VegF level in the vitreous are plotted for the PDr group (circles) and 
AhFVP group measured at each operation (open square). 
Abbreviations:  VegF,  vascular  endothelial  growth  factor;  PDr,  proliferative 
diabetic retinopathy; AHFVP, anterior hyaloidal fibrovascular proliferation.
Figure 1 intraoperative photograph of Case 1 with AhFVP undergoing membrane 
removal with vitreous cutter.
Abbreviation: AhFVP, anterior hyaloidal fibrovascular proliferation.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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peripheral retina had been ablated by retinal photocoagulation 
at the primary operation. Vitreous hemorrhage developed 
8 months after the primary surgery, and a third vitrectomy 
was performed. AHFVP was detected at the time of this 
surgery (Figure 1). The VEGF level at this vitrectomy was 
still high at 39.00 ng/mL.
In Case 2 (white square in Figure 2), the VEGF level at the 
primary vitrectomy was 1.94 ng/mL, which was comparable to 
that in the PDR group (Figure 2). Three weeks later, a   second 
vitrectomy was performed to remove a persistent vitreous 
hemorrhage, and the VEGF level in the vitreal sample had 
increased to 11.20 ng/mL despite an ablation of the peripheral 
retina by photocoagulation at the primary operation. Seven 
weeks later, we performed membrane peeling and additional 
photocoagulation because of a reproliferation, and the VEGF 
level at this time was 15.60 ng/mL. Seven months after the first 
operation, vitreous hemorrhage recurred, and a 4th operation 
was performed. During the surgery an AHFVP was identified, 
and the vitreous sample collected showed that the VEGF level 
was decreased but still high at 5.70 ng/mL.
In Case 3 (gray square in Figure 2), the VEGF level was 
8.07 ng/mL at the primary vitrectomy with cataract surgery 
and trabeculectomy. Six months later, the operated eye 
developed hyphema. During the 2nd operation, an AHFVP 
was identified, and the vitreal sample showed that the VEGF 
level was markedly increased to 50.60 ng/mL.
The VEGF level of the AHFVP group overlapped that of 
the PDR group at the primary surgery. However, the VEGF 
concentration in the AHFVP group was increased after the 
primary surgery beyond the upper limit in the PDR group 
(Figure 2). The VEGF level at subsequent surgeries was 
more than five times higher than the baseline at the primary 
surgery in all AHFVP cases.
Discussion
Our results demonstrated that the VEGF level in the vitreous 
sample considerably increased after the primary surgery in 
eyes that developed AHFVP. This suggests a pathological 
association between the intravitreal VEGF level and the 
development of AHFVP.
It has been reported that VEGF is upregulated by inflam-
matory cytokines such as IL-1 and TNF-α.4,5 Our AHFVP 
cases underwent intensive retinal photocoagulation with long 
operation times that could possibly have upregulated these 
inflammatory cytokines, which would then upregulate the 
expression of VEGF. If they are upregulated, then studies 
should be performed to see if suppressing these   inflammatory 
cytokines by triamcinolone acetonide can prevent the 
  development of AHFVP.
Anti-VEGF therapy, eg, by bevacizmab, has been shown 
to be an effective therapy for the neovascularization in eyes 
with PDR.6 Based on our results that VEGF may play a role 
in the development of AHFVP, anti-VEGF treatment may 
be effective as an adjunctive treatment in preventing the 
development of AHFVP. Because anti-VEGF therapy was 
not available during the study period, we could not test this 
hypothesis. Future studies are necessary to determine the 
efficacy of anti-VEGF therapy for AHFVP.
There are some limitations of this study. First, AHFVP 
is a rare complication so that we were able to study only 
three patients. Second, the level of VEGF level was quite 
  variable among cases in the AHFVP group. However, the 
VEGF level in the eyes with AHFVP was higher than the 
highest level in the PDR group after the primary surgery and 
at the subsequent vitrectomies. The VEGF level was increased 
to more than five times higher than the baseline level at the 
primary surgery in all AHFVP cases. The increase of the 
VEGF level is much higher than that reported in diabetic 
patients who underwent vitrectomy.7 These findings support 
our   conclusion that the intravitreal level of VEGF is associ-
ated with the development of an AHFVP.
In case 2, the VEGF level was higher than the normal range; 
however, the VEGF level at onset of AHFVP was lower than 
the other cases. From this, we suggest that the development 
of AHFVP may be caused by not only VEGF but also other 
factors. Although VEGF plays a major role in progression of 
diabetic retinopathy, the level at the onset of AHFVP may be 
different in each case, and could be affected by sensitivities 
of the receptors, inhibitors,8 and other factors associated with 
the upregulation of VEGF.9 We examined only the VEGF 
level as main factor of diabetic retinopathy. However, other 
factors may also maintain the neovascularization, and further 
studies will be necessary to determine whether other factors are 
involved in the development of AHFVP. Our results   suggest 
that not only anti-VEGF therapy but also anti-cytokine therapy 
should be considered in future studies.
Our results strongly suggest that intravitreal VEGF plays 
an important role in development of AHFVP.   Therefore, it 
would be useful to measure the VEGF level in the   vitreous 
during the vitreous surgery for diabetic retinopathy to be able 
to predict the possibility of a development of AHFVP.
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